307. Predictors of Respiratory Bacterial Co-Infection in Hospitalized COVID-19 Patients

Erica E. Reed, PharmD, BCPS-AQ ID¹; Austin Bolker, PharmD, MBA¹; Kelci E. Coe, MPH²; Jessica M. Smith, PharmD, MBA, BCIDP¹; Kurt Stevenson, MD, MPH³; Shu-Hua Wang, MD, PharmD¹; ¹The Ohio State University Wexner Medical Center, Columbus, OH; ²Ohio State University Wexner Medical Center, Columbus, OH; ³The Ohio State University College of Medicine and College of Public Health, Columbus, Ohio

Session: P-14. COVID-19 Complications, Co-infections, and Clinical Outcomes

Background. COVID-19 pneumonia can be indistinguishable from other infectious respiratory etiologies, so providers are challenged with deciding whether empiric antibiotics should be prescribed to hospitalized patients with SARS-CoV-2. This study aimed to evaluate predictors of respiratory bacterial co-infections (RBCI) in hospitalized patients with COVID-19.

Methods. Retrospective study evaluating COVID-19 inpatients from Feb 1, 2020 to Sept 30, 2020 at a tertiary academic medical center. Patients with RBCI were matched with three COVID-19 inpatients lacking RBCI admitted within 7 days of each other. The primary objectives of this study were to determine the prevalence of and identify variables associated with RBCI in COVID-19 inpatients. Secondary outcomes included length of stay and mortality. Data collected included demographics; inflammatory markers; bacterial culture/antigen results; antibiotic exposure; and COVID-19 severity. Wilcoxon rank sum, Chi Square tests, or Fisher's exact tests were utilized as appropriate. A multivariable logistic regression (MLR) model was conducted to identify covariates associated with RBCI.

Results. Seven hundred thirty-five patients were hospitalized with COVID-19 during the study period. Of these, 82 (11.2%) had RBCI. Fifty-seven of these patients met inclusion criteria and were matched to three patients lacking RBCI (N = 228 patients). Patients with RBCI were more likely to receive antibiotics [57 (100%) vs. 130 (76%), p < 0.0001] and for a longer cumulative duration [19 (13-33) vs. 8 (4-13) days, p < 0.0001] compared to patients lacking RBCI. The MLR model revealed risk factors of RBCI to be admission from SNF/LTAC/NH (AOR 6.8, 95% CI 2.6-18.2), severe COVID-19 (AOR 3.03, 95% CI 0.78-11.9), and leukocytosis (AOR 3.03, 95% CI 0.99-1.16).

Conclusion. Although RBCI is rare in COVID-19 inpatients, antibiotic use is common. COVID-19 inpatients may be more likely to have RBCI if they are admitted from a SNF/LTAC/NH, have severe COVID-19, or present with leukocytosis. Early and prompt recognition of RBCI predictors in COVID-19 inpatients may facilitate timely antimicrobial therapy while improving antimicrobial stewardship among patients at low risk for co-infection.

Disclosures. All Authors: No reported disclosures

308. Secondary Infections in Patients Requiring Extracorporeal Membrane Oxygenation (ECMO) for Severe Acute Respiratory Distress Syndrome (ARDS) due to COVID-19 Pneumonia (PNA)

Ryan Rivosecchi, PharmD, BCCCP¹; J. Alex Viehman, MD²; Christina K. Thorngren, MD, MPH¹; Ryan K. Shields, PharmD, MS²; Fernanda P. Silveira, MD, MS, FIDSA²; Fernanda P. Silveira, MD, MS, FIDSA²; Eun Jeong Kwak, MD²; Peter Volpe, MD³; Vidya Jagadeesan, MD⁴; Cornelius J. Clancy, MD²; Minh Hong Nguyen, MD¹; Palash Samanta, MD²; ¹UPMC Presbyterian Hospital, Pittsburgh, PA; ²University of Pittsburgh, Pittsburgh, Pennsylvania; ³University of Pittsburgh Medical Center, Pittsburgh, PA; ⁴UPMC, Pittsburgh, Pennsylvania

Session: P-14. COVID-19 Complications, Co-infections, and Clinical Outcomes

Background. Rescue ECMO has been used worldwide in patients (pts) with ARDS caused by COVID-19. Bacterial super-infections affect 3.5-14.3% of hospitalized pts with COVID-19. Pts requiring ECMO may be at an increased risk of infection due to their severity of illness, gut translocation and ECMO impact on host immunity.

Methods. This was a retrospective review of pts requiring ECMO for COVID-19 from April 2020-2021 at a single center. Strict definitions of infections (including ventilator-associated PNA, VAP) were in accordance with CDC criteria.

Results. 43 ECMO pts with 1065 ECMO days were evaluated. Median age was 53 yrs (range: 21-62) and median BMI was 36.2 (range: 19.4-75.8). 70% were men and 65% were white. 37 patients (86%) experienced a total of 40 infectious episodes with a median onset from ECMO cannulation to first infection of 10.5d (range: 4-50). Median SOFA and SAPSII scores at time of infection were 12 (6-20) and 63 (30-90), respectively. PNA was the most common infection (78%, with 19% of cases complicated by bacterenia and 3% by empyema) (Fig. 1). The most common organisms isolated were Enterobacterales (37%), *S. aureus* (25%) and *P. aeruginosa* (16%) (Fig. 2). Only 2% of all organisms were multi-drug resistant. 3 pts had fungal infections (1 candidemia, 2 aspergillus PNA). Duration of ECMO was significantly longer for infected pts (26d, range: 5-92d) vs (11d, range: 3-24d), p=.01. 95% of infected pts had recurrent infections and Pareived start. Week was 50%, and 24% and 40% of pts had recurrent infections and persistent/recurrent organisms in clinical

cultures, respectively. *S. aureus* (54%) and Enterobacterales (26%) were associated with persistent or recurrent clinical cultures, requiring prolonged antimicrobial therapy. Mortality rate at 30 days was 65% and was significantly higher for pts with infection than those without (67% vs 33%, p=.02).



Fig.1 Types of infections among COVID-19 patients on ECMO



Fig 2. Organisms causing infection

Conclusion. Super-infection (most commonly PNA) occurred in almost all COVID-19 pts requiring ECMO for >4 days, and was a significant risk factor for death. Recurrent infections among survivors were common, especially when caused by Enterbacterales or *S. aureus.* Super-infection and mortality rates of ARDS pts on ECMO for COVID-19 were worse than for ARDS pts on ECMO for influenza at our center.

Disclosures. Ryan K. Shields, PharmD, MS, Shionogi (Consultant, Research Grant or Support) Fernanda P. Silveira, MD, MS, FIDSA, Ansun (Individual(s) Involved: Self): Grant/Research Support; Novartis (Individual(s) Involved: Self): Grant/Research Support; Shire (Individual(s) Involved: Self): Advisor or Review Panel member, Grant/Research Support; SlieaGen (Individual(s) Involved: Self): Grant/Research Support; Whiscon (Individual(s) Involved: Self): Grant/Research Support; Movartis (Individual(s) Involved: Self): Grant/Research Support; Mbiscon (Individual(s) Involved: Self): Grant/Research Support; MD, Merck (Grant/Research Support)

309. TB Quantiferon Testing Predicts Mortality in Patients with COVID-19

Mirza Z. Baig, MD¹; Siyun Liao, PharmD, PhD, BCPS, BCIDP²; Margaret Powers-Fletcher, PhD¹; Moises A. Huaman, MD, MSc¹; Senu Apewokin, MD¹; ¹University of Cincinnati, Mason, Ohio; ²UC Health-University of Cincinnati Medical Center, Cincinnati, OH

Session: P-14. COVID-19 Complications, Co-infections, and Clinical Outcomes

Background. Finding reliable clinical predictors for severity of COVID-19 has been challenging. Interferon gamma (IFNG) plays an important role in viral replication. QuantiFERON-TB (QFT) test relies on IFNG release in response to antigens. A positive or negative test signifies adequate IFNG response, whereas an indeterminate result is obtained when such a response is lacking. In this study, we have attempted to see if an indeterminate QFT result can provide prognostic information on patients with COVID-19.

Survival Probability in patients with Covid - 19 and an indeterminate TB Quantiferon test result